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Abstract: Although respiratory syncytial virus (RSV) is one of the leading causes of acute respiratory
tract infection in infants and adults, effective treatment options remain limited. To circumvent
this issue, there is a novel approach, namely, the development of multifunctional liposomes for
the delivery of anti RSV-peptides. While most of the peptides that are used for loading with the
particulate delivery systems are the penetrating peptides, an alternative approach is the development
of liposome-peptide systems, which are loaded with an RSV fusion peptide (RF-482), which has
been designed to inhibit the RSV fusion and block infection. The results of this work have revealed
that the liposomes themselves can serve as potential RSV inhibitors, whilst the anti-RSV-peptide
with liposomes can significantly increase the RSV inhibition when compared with the anti-RSV
peptide alone.
Keywords: liposomes; respiratory syncytial virus; peptide; hydrophilic
1. Introduction
Respiratory syncytial virus (RSV), as well as Rhinovirus (HRV), are the primary causes of acute
lower respiratory tract (LRTI) infections [1]. An RSV infection is particularly noticeable during winter
for populations, including the fetus, infants [2], young children, and adults [3–5]. A focused cause of
bronchitis and pneumonia is RSV. It is widely recognized that there is a need for a vaccine against RSV,
as the natural infection is not capable of providing life-long immunity and patients are prone to suffer
from repeated RSV infection [6].
RSV, which belongs to the Pneumoviridae family, is a distinct serotype that has two major antigenic
circulating subgroups (A & B), of which the A is dominant [5,7,8]. RSV has an RNA genome
consisting of 15,191 base pairs. The virus can be identified with 11 proteins, including 2-non-structural
proteins (NS-1 and NS-2), 3-surface proteins (glycoprotein-G, fusion protein-F, and small hydrophobic
protein-HP), two overlapping frames of M2 mRNA producing 2 distinct transcription factors (M-1 and
M-2), and four other structural proteins (matrix protein-M, nucleocapsid-N, phosphoprotein-P,
and large protein-L) [5]. The viruses of the Pneumoviridae family fuse their membrane with the plasma
membrane of the host, which results in a cell fusion if it is added to the cell in large quantity [9].
The entry of the RSV virus into the host cells occurs with the aid of the fusion protein-F, which has two
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hepated-repeated regions that form a hairpin-like structure, which facilitates the entrance of the virus
into the cells [10].
The root cause analysis of any disease or disorder is at the foundation of the treatment design.
An infection of RSV can start with a mild upper respiratory tract infection (URTI) and may lead to a
potentially precarious lower respiratory tract infection [5]. RSV transmission occurs from person to
person contact, directly or indirectly; an RSV infected person, upon sneezing or coughing, can leave
viral droplets suspended in the air, which have the potential for transmission of the infection by
entering the healthy individual through the mouth, nose, or eyes [11].
The first line treatment of RSV infection is the use of bronchodilators, such as α and/or β
adrenergic agonist [5]. For pediatrics, since corticosteroids are not approved for treating RSV-infected
individuals that are less than 1 year old, because of safety concerns [12], the use of vaporub and
non-aspirin formulations, such as paracetamol, are the treatments of choice prior to clinical attention.
Of the very few options available for the treatment of RSV, Ribavirin, a broad spectrum antiviral drug,
is used. Although this too comes with limitations and drawbacks [13]. Despite several concept studies
that have claimed the effectiveness of ribavirin in significantly reducing the RSV load and minimizing
the disease severity, the disadvantages of the mutagenicity, teratogenicity, and carcinogenicity have
subsequently resulted in FDA denial [14]. An active rather than passive prophylaxis would be a better
choice but, unfortunately, there is no current vaccine that has been developed for the RSV infection.
The formalin-inactivated vaccine was launched in the 1960s but was later withdrawn because of
inadequate immunogenic responses, as well as an atypical TH2-type response, which increases the
chances of reinfection with similar or deadly infections [12].
The use of nanoparticulate systems, such as liposomes, can provide adjuvant action by an
enhanced antigen delivery or by inducing an innate immune response [15]. Commercially, liposomes
are the most successful carrier systems across the globe. Liposomes are vesicles with an aqueous
core, which are surrounded by a phospholipid bilayer. From the numerous pre-clinical and clinical
studies, it is clear that those liposomes are not only carriers of the chemical and biological materials,
but they are also non-toxic and good at retaining efficacy. Indeed, the potential of the liposomes to act
as a latent carrier of active pharmacological agents is well established [16–18], whilst liposomes have
also shown their ability to carry antigens and to serve as immunomodulators [19]. Recently, a novel
approach to inhibit the RSV has been the use of gold nanoparticles (GNPs) [20]. These GNPs can
be functionalized with nucleic acid, antibodies, drugs, and peptides, and these functionalized GNPs
then can be applied in the diagnosis or treatment of the diseases [21]. The anti-RSV fusion peptide
RF-482 (sequence: VFPSDEFDASISQVNEKINQSLAFIRKSDLLHNVNAGKK) is used to functionalize
the GNPs, and a significant inhibition of the RSV was observed after the loading of the GNPs [20].
The liposomes can be loaded with peptides, however insufficient research has been performed using
liposomes as carrier systems for the inhibition of RSV [22–24]. Therefore, considering the global need
and structural attributes of liposomes, this work describes an approach that employs the liposomes for
the loading of RF-482, for the enhanced inhibition of RSV.
2. Materials and Methods
2.1. Materials
The lipid 1,2-disteroylphosphatidylcholine (DSPC) was purchased from Avanti Polar Lipids,
Inc. (Alabaster, AL, USA). The cholesterol was obtained from Sigma-Aldrich Co. (St Louis, MO,
USA). The minimal essential medium (MEM), Dulbecco’s Modified Eagle’s media (DMEM), Hank’s
balanced salt solution (HBSS), fetal bovine serum (FBS), 7-amino actinomycin D (7-AAD), L-glutamine
(100 mM), antibiotics, TrypLE™, Lipofectamine 2000, real-time probe, primers, SuperScript® II Reverse
Transcriptase, and TaqMan® Master Mix 2× were purchased from Life Technologies (Thermo Fisher
Scientific, Waltham, MA, USA). Both the DNA and ribonucleic acid (RNA) isolation kits were purchased
from Qiagen (Germantown, MD, USA). The human epithelial type 2 (HEp-2) cells were obtained from
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American Type Culture Collection (ATCC®, Manassas, VA, USA). The cell toxicity was analyzed using
the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) dye-based cell proliferation
assay kit from Promega Corp (Madison, WI, USA). The osmium tetroxide (4% solution) that was used
for the fixative staining of the liposomes was purchased from Electron Microscopy Sciences (Hatfield,
PA, USA). The ethanol was purchased from Fisher Scientific, Fair Lawn, NJ, USA. All of the reagents
that were used for the experiments were of analytical grade.
2.2. Preparation of Small Unilamellar Liposomes
The liposomes were prepared using the thin-film hydration method [25]. Briefly, the lipid
DSPC and cholesterol (5:2 w/w) were dissolved in an organic solvent mixture of chloroform and
methanol, with the addition of the lipophilic drug, followed by a solvent evaporation to obtain a thin,
dry film. The film was then hydrated with a phosphate buffered saline (PBS) (1 mM, pH 7.4, 25 ◦C),
which resulted in the formation of the multi-lamellar vesicles (MLV). This MLV suspension was then
sonicated using a probe sonication so as to obtain small unilamellar vesicles (SUV). The sonicated
liposomal suspension was then centrifuged to remove titanium debris.
2.3. Loading of Peptide
The liposomal suspension was obtained after the removal of the titanium debris was used for
the peptide loading. The RF-482 (500 µg) was added to the liposomal suspension (2.0 mL) and it
was subjected to the mechanical shaking for 30 min. The non-associated peptide was then removed,
using centrifugal filter units (Ultracel-50K, Millipore Ireland Ltd., Cork, UK). The RF-482 loaded
liposomes were then used for further studies.
2.4. Particle Characteristics
Dynamic light scattering (DLS) (Zetasizer Nano-S, Malvern Instruments, Westborough, MA,
USA) was used for the size determination of the empty and RF-482 loaded liposomes. The zeta
potential was determined using the laser Doppler velocimetry (Zetasizer Nano-S, Malvern Instruments,
Westborough, MA, USA). The samples were prepared using the PBS that was diluted 1–300 times
(pH 7.4, 25 ◦C).
2.5. Transmission Electron Microscopy (TEM)
Osmium tetroxide has commonly been used for the fixative stain for cells in the TEM analysis.
Since the liposome structure resembles cell structure, a similar fixative staining was performed in this
study. Briefly, a drop of each liposome sample was placed on to the carbon film mesh copper grid,
and the excess suspension was removed using a filter paper. The staining was performed using a 4%
osmium tetroxide solution and the images were captured using a high-resolution TEM (EM10A/B,
ZEISS, Oberkochen, Germany).
2.6. Quantification of Peptide Association
After the separation of the associated and non-associated peptide, the eluent and the liposome
suspension were tested for peptide presence using the micro bicinchoninic acid (BCA) assay kit
(Thermo Scientific, Rockford, IL, USA), according to the manufacturer’s protocol. Briefly, the standard
curves were prepared using the RF-482 peptide, for linearity and calibration. All of the samples were
diluted using PBS, and since ethanol was used to separate the liposome associated protein, this was
also further diluted with PBS. The standards and samples (150 µL each) were each added to wells
of a 96-well plate, which was followed by the addition of 150 µL of working reagent and incubation
for 2 h at 37 ◦C. The plate was then cooled to room temperature, and the absorbance measurements
were taken at 562 nm, using an ELISA plate reader (TECANTM, Morrisville, NC, USA). Apart from the
standards and samples, the ethanol, buffer, and empty liposomes were tested for BCA interference.
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2.7. Cell Viability Assay
The CellTiter 96® Non-Radioactive cell proliferation assay kit (Promega) and the MTT
(3-(4,5-dimethyl-thiazol-2-yl)-2,5-diphenyl-tetrazolium bromide) dye was used to assess the cell toxicity
of the empty and peptide-loaded liposomes, as well as the peptide RF-482 to human HEp-2 cells.
The human HEp-2 cells were propagated using MEM, which was supplemented with 10% FBS, 2 mM
L-glutamine, 75 U/mL penicillin, 100 mg/mL kanamycin, and 75 mg/mL streptomycin (MEM-10).
Each well of a 96-well plate was seeded with 25,000 cells and incubated overnight at 37 ◦C in a 5% CO2
atmosphere for adherence. Two different concentrations of the peptide RF-482 (0.01 mg and 0.02 mg),
empty liposomes and peptide-loaded liposomes were added to the wells, and the cell toxicity was
assessed 72 h post incubation. The absorbance was measured at 570 nm, using an ELISA plate reader
(TECANTM). The percent viability was then calculated from a comparison of the samples against the
negative control.
2.8. Fluorescence Microscopy
The fluorescein isothiocyanate (FITC) labeled peptide RF-482 was used to demonstrate the
association of the peptide with the liposomes. However, in order to study the RSV inhibition,
30,000 cells per well were seeded into an 8-chambered slide. The cells were incubated with
peptide RF-482, empty liposomes, and peptide-loaded liposomes for 48 h, followed by fixing it
in a paraformaldehyde-glutaraldehyde and buffer (PBS) wash. The nuclei were stained using DAPI
and the cell membranes were stained using Cell Mask™ (Life Technologies). All of the chamber slides
were imaged using the DAPI and FITC channels of the Nikon Ti Eclipse fluorescence microscope
(Nikon Inc. Melville, NY, USA).
2.9. Plaque Assay
The plaque assay was one of the most common and reliable methods for the determination of
the viral/antiviral activity in the cell cultures. The plaque assay was performed using the HEp-2 cells
(1.5 × 105/well) that were cultured in MEM-10 for 48 h, in order to achieve a maximum confluency.
Dilutions of a mixture of RSV and peptide, empty liposome, and peptide-loaded liposomes were
prepared in DMEM before the infection. Post-infection, the cells were covered by immobilizing the
overlaying medium (1.6% Methylcellulose) and were subsequently incubated for five days at 37 ◦C
in 5%, CO2 environment. On day 5, the overlaying medium was removed, and the monolayer was
fixed with cold methanol at −20 ◦C, followed by being stained with a 0.1% crystal violet solution.
The plaques were counted in order to determine the viral or antiviral activity.
2.10. TaqMan qPCR Analysis
The HEp-2 cells (1.5 × 105/well) were seeded in 12-well plates, followed by treatment with
varied RSV dilutions (102 to 108), with and without the peptide, empty liposomes, or peptide-loaded
liposomes. These treated cells were then incubated for 48 h at 37 ◦C in a 5% CO2 environment,
which was followed by being harvested for RNA extractions. A total of 1 µg RNA/sample was
converted to cDNA, using reverse transcriptase according to the manufacturer’s protocols (Applied
Biosystems, Waltham, MA, USA). TaqMan qPCR was performed for the amplification of the RSV-F
gene, using the RSV-F gene-specific primers and probe, and previously published procedures [26,27].
The RSV-F gene amplicon dilutions (102 to 108) were used as the standards. The qPCR for each
sample was run in a duplicate on the Applied Biosystems® ViiA™ 7 real-time PCR (Life Technologies).
The fold changes were calculated by comparing the untreated cells.
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2.11. Statistical Analysis
Unless stated otherwise, the results were calculated as the mean ± standard deviation (SD).
The data were analyzed by the student’s t-test, alone, or by ANOVA, which was followed by Dunnett’s
post-hoc analysis for comparison. The significance was acknowledged for p values < 0.05.
3. Results
3.1. Confirmation of Peptide Loading
Liposomes are spherical vesicles made up of phospholipids [25]. Upon the hydration of a thin lipid
film, MLVs were formed by vortexing and heating the suspension above the transition temperature
(Tc) of the lipid. These MLVs could then be transformed into SUV by a variety of methods, including a
probe sonication, which was used in this study. The liposomes were one of the most flexible structures
that conjugate moieties, like lactose and peptide [22,28]. There was a slight change in the size of the
liposome that was observed after the loading with RF-482 (Figure 1).
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Figure 2. Fluorescence microscopy analysis of the presence of the fluorescein isothiocyanate
(FITC)-labeled peptide RF-482 (green) confirms association with liposomes (40× magnification) (a).
Transmission electron microscopy analysis. Comparison between the empty liposomes (c) and the
RF-482 peptide-loaded liposomes (b).
3.2. Quantification of Loading
The exact mechanism of the protein–liposome association is still unknown. However, it was
confirmed by the fluorescence microscopy as well as the TEM that the peptide RF-482 was associated
with the liposomes. Since the association of the peptide–liposome was confirmed, it was necessary to
quantify the amount of protein that was loaded with the liposomes. However, it was equally important
to achieve the mass balance so as to study the actual amount of loading of the peptide. Hence, the BCA
assay was performed for the analysis of both the eluent and liposome samples. It was confirmed that
81.7% ± 0.1% (n = 3) was not loaded and that 19.1% ± 0.4% (n = 3) was loaded (Figure 3). This also
confirmed the 100% recovery of the initial amount of the peptide.
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(n = 3 ± standard deviation (SD)).
3.3. Cell Toxicity Analysis
The peptide, liposomes, and peptide-loaded liposomes, all at two different concentrations,
were tested for their cell toxicity. There was no toxicity observed with both of the concentrations of all
of the samples. After 72 h of incubation, the observed cell viability was more than 80% (n = 3 ± SD) for
the chosen concentrations of the peptide RF-482. Whereas, in the case of the liposome alone, both of
the concentrations of lipids were found to be completely non-toxic. However, when the peptides
were loaded on to the liposomes, the toxicity was reduced slightly, as the cell viability for the chosen
concentrations were observed to be ~90% (n = 3 ± SD). (Figure 4).
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3.4. Evaluation of Viral Inhibition
The plaque reduction assay has been known as the optimum standard for the antiviral activity
analysis [29]. During the plaque assay, the monolayer of the HEp-2 cells was infected with the lytic
RSV. The infected cells experienced lytic cycles and eventually appeared as plaques or, in other
words, zones of cell death [30]. It was reported recently that the surfactant phospholipids that were
bound to the RSV had markedly suppressed the infection though fusion inhibition [31]. We tested
the anti-RSV peptide, liposomes, and liposome loaded peptide against RSV infection to HEp-2 cells.
When these plaques were counted, it was observed that, although the peptide RF-482 and liposomes
alone were capable of inhibiting the RSV, when they were combined, the peptide-loaded liposomes
had a significant increase in RSV inhibition (p < 0.05, ANOVA, post hoc Dunnett’s multiple comparison
tests) (Figure 5). Also, it was an interesting finding that the liposomes alone could also inhibit the RSV,
and significantly more so (p < 0.05, ANOVA, post hoc Dunnett’s multiple comparison tests) than the
peptide RF-482 alone.
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Figure 5. Screening of peptide, liposomes, and peptide encapsulated against respiratory syncytial virus
(RSV). Plaques were counted, and the mean plaque was a count of each sample, which was expressed
as a percentage of the mean count of the control. (n = 3 ± SD). Significant differences between the
samples represented as * p < 0.05 and ** p < 0.01.
To validate the plaque assay results, qualitative and quantitative testing as perfor ed.
I unofluorescence imaging was used as a qualitative tool, whilst PCR was employed as a
quantitative tool. The cells were incubated for 48 h with the peptide RF-482, empty liposomes,
and peptide-loaded liposomes, followed by being fixed in a paraformaldehyde-glutaraldehyde and
being washed with a buffer (PBS). An appropriate chamber from the eight-chambered slide was
observed under the fluorescence microscope for the RSV activity. The observation that was made
from this analysis (Figure 6) was concurrent with the findings that were obtained from the plaque
assay (Figure 5) and confirmed that the peptide RF-482, liposomes, and peptide-loaded liposomes,
were capable of inhibiting the RSV.
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In liposomes and RF-482 liposomes, the blue color represents the survived cells, and the green color
represents the presence of RSV.
Having the confirmation from the microscopic observation of the viral inhibition, it was necessary
to quantitatively validate the plaque assay results. A significant difference (p <0.05, ANOVA,
post hoc Dunnett’s multiple comparison tests) was observed between a number of gene copies of the
virus sample and samples having the peptide, liposomes, or peptide-loaded liposomes (Figure 7).
This confirmed that the peptide RF 482, liposomes, and peptide-loaded liposomes were equally capable
of inhibiting the RSV. However, although there was no significant difference (p >0.05, t-test) observed
between the peptide, liposome alone, and peptide-loaded liposomes, the loaded liposome samples
displayed a trend for slightly lower gene copies, which indicated slightly more inhibition than the
individual components when used solely (Figure 7).
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4. Discussion
To date, the F, G, M, and small hydrophobic proteins have been considered as targets so as to avoid
the RSV infection [23,32–34]. Nearly a dozen peptide-based formulations have been under clinical
trials, and most of these are targeting the F-protein [35–37]. However, the role of the F-protein is vital
in the spread of the virus, because targeting the G-protein could neutralize the virus, however the
actual spread of the virus is only possible after inhibiting the F-protein [38–40]. Over a decade ago,
studies were suggested that all of the three F-, G-, and RSV-SH protein inhibitors could be used for
the complete RSV inhibition [41]. However, within the last decade, several reports indicated that only
the F-protein was capable of inhibiting the RSV infection [42,43]. Therefore, some recent studies have
specifically targeted the F-protein [20,44,45]. For example, Singh et al. described that the anti-RSV
peptide RF-482 was an F-protein inhibitor and was used to functionalize the GNPs, and a significant
inhibition was reported after the loading of the GNPs [20].
With the quest of finding an alternative carrier for delivering the anti-RSV peptide RF-482,
the liposome formulations were prepared here and were tested for the inhibition of the RSV infection.
RF-482 was a small fusion peptide with 39 amino acids, with a total of 611 atoms [20]. Since it was a
fusion of the peptide and hydrophilic, it was expected that the RF-482 might have gotten entrapped in
the hydrophilic core and that it might have been adsorbed on the surface of the liposomes. Although the
exact mechanism of the peptide association with the liposomes was unrevealed, the functionalization
of the liposomes was confirmed through the dynamic light scattering (Figure 1), change in the surface
charge (Figure 1), fluorescence imaging (Figure 2c), and transmission electron microscopy (Figure 2a,b).
Knowing that the toxicity was an emerging problem in the RSV treatment [7], it was one of
the primary objectives when designing the treatment for the RSV infection. The liposomal research
to date described them as a system that could be used, not only as a delivery system, but also as
adjuvants [15,46,47]. Designing the protein-based liposomal adjuvant vaccine could be an approach
to attaining a maximum efficacy and low toxicity [48]. Similarly, in this scenario, the liposomes had
shown their non-toxic nature for the chosen HEp-2 cells for 72 h, which reflected their potential
application in designing the RSV treatment. The cytotoxicity of the various concentrations of these
liposomes was tested by the MTT assay, and it was found that the liposome formulations of two
different concentrations of lipids, with and without protein loading, did not render any cytotoxic effect
or molecular effect on the host HEp-2 cells (Figure 4).
Amongst the several ways of viral inhibition analysis, the plaque assay, immunofluorescence
microscopy, and qPCR were considered as standard tools [13,21,49]. The anti-RSV effect was therefore
confirmed in the plaque assay (Figure 5), immunofluorescence imaging (Figure 6), and qRT-PCR.
The anti-RSV activity of the peptide RF-282 had already been reported, but an interesting finding
confirmed the inhibition of the RSV in the presence of the DSPC cholesterol liposomes, which resembled
the results from Hendricks et al., where the decoy liposomes were found to be capable of inhibiting
RSV from cellular binding [23]. The functionalization of the gold nanoparticles using the anti-RSV
peptide was shown to have a significant effect on the RSV inhibition, compared with the peptide
alone [20,21]. Similarly, our results also confirmed that the RSV percent inhibition was significantly
increased (p <0.05) for the RF-482 loaded liposomes compared with the RF-482 and liposomes alone
(Figures 5 and 7).
Overall, our research demonstrated that the RF-482 itself was capable of inhibiting RSV,
but the inhibition of RSV was significantly increased with the loading on the liposome.
Moreover, recent reports showed that phosphatidylinositol (PI) inhibited the respiratory syncytial
virus (RSV), as the PI bound the RSV with a high affinity, which inhibited its fusion to the epithelial
cells [31,50]. There were five derivatives of the phospholipids, including the PI and the phosphocholine
(PC). Although the exact mechanism of RSV inhibition by PC was not confirmed, it was possible
that, similarly to the PI, the PC could have an affinity towards the RSV, inhibiting its fusion to the
epithelial cells. However, the liposomal loading of the anti-RSV agents, like RF-482, were shown
to have decreased the viral activity of RSV. Liposomes are multifaceted delivery systems and are
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capable of co-encapsulating compounds depending on their characteristics [51]. This structural
attribute of the liposomes could become a carrier of multiple proteins and/or other anti-RSV
compounds. Liposomes could be designed to look like a virus, by attaching multiple proteins to it [52].
Therefore, liposomes are multifaceted systems and hold the potential of entering the mainstream for
designing the prophylaxis against RSV infection.
5. Conclusions
RF-482 has been reported as an inhibitor of RSV fusion and, to date, gold nanoparticles are the
only reported carrier of RF-482 [21]. However, liposomes have been considered as an alternative
carrier for delivering the anti-RSV peptide, RF-482. Moreover, the liposomes, as a new candidate
for RSV inhibition, have been tested and the inhibitory effect of the liposomes has been shown
to be better compared with the peptide alone, while the peptide-loaded liposomes have proved
to be a better candidate for the RSV inhibition compared with both the peptide and liposomes
alone. However, this has generated another quest to unveil the exact mechanism of the RSV infection
inhibition, using the liposomes or peptide-loaded liposomes, which could lead to the commercialization
of the formulation.
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